NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study

Phase 1

Withdrawn

Conditions: SARS

Interventions: Drug: Aluminum hydroxide adjuvant (Alhydrogel®)
Other: Phosphate buffered saline Placebo
Biological: Recombinant S protein SARS vaccine

First Posted Date: 2011-06-20

Last Posted Date: 2013-02-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT01376765

Locations: 🇺🇸
Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States
🇺🇸
Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States
🇺🇸
University of Iowa - Infectious Disease Clinic, Iowa City, Iowa, United States

Screening Volunteers for Clinical Trials

Recruiting

Conditions: Screening

First Posted Date: 2011-06-17

Last Posted Date: 2025-06-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 4000

Registration Number: NCT01375530

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
University of Pennsylvania-UPenn, Philadelphia, Pennsylvania, United States
🇺🇸
Univ of MD School of Medicine Center for Vaccine Development & Global Health, Baltimore, Maryland, United States

and more 1 locations

Perceived Barriers to Patient Adherence After Pediatric Solid Organ Transplantation

Completed

Conditions: Organ Transplantation

First Posted Date: 2011-06-10

Last Posted Date: 2017-06-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 502

Registration Number: NCT01370746

Locations: 🇺🇸
Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, United States
🇺🇸
Children's Hospital of Boston, Boston, Massachusetts, United States
🇺🇸
Ronald Reagan UCLA Medical Center (Mattel Childrens'), Los Angeles, California, United States

and more 12 locations

Extended Follow-Up After Islet Transplantation in T1D

Completed

Conditions: Type 1 Diabetes (T1D)
Islet Transplantation

Interventions: Drug: Maintenance Immunosuppressive Treatment

First Posted Date: 2011-06-08

Last Posted Date: 2017-11-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 75

Registration Number: NCT01369082

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States

and more 5 locations

Persistence of Oral Tolerance to Peanut

Phase 2

Completed

Conditions: Eczema
Food Allergy
Hypersensitivity
Egg Allergy

Interventions: Other: Avoidance of peanut

First Posted Date: 2011-06-06

Last Posted Date: 2017-03-10

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 556

Registration Number: NCT01366846

Locations: 🇬🇧
Evelina Children's Hospital, London, United Kingdom

Preventing the Spread of Malaria in Mali

Completed

Conditions: Malaria

First Posted Date: 2011-05-25

Last Posted Date: 2019-11-07

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 816

Registration Number: NCT01360112

Locations: 🇲🇱
University of Bamako, Faculty of Medicine, Pharmacy and Odontostomatology, Bamako, Mali

Phase IC Study of Safety and PK of SQ109 300mg Daily

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Drug: SQ109
Other: Placebo

First Posted Date: 2011-05-23

Last Posted Date: 2013-05-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 10

Registration Number: NCT01358162

Locations: 🇺🇸
Quintiles Phase I Services - Overland Park, Overland Park, Kansas, United States

Phase 1 PK Study of XOMA 3AB

Phase 1

Completed

Conditions: Botulism

Interventions: Drug: XOMA 3AB
Other: Placebo

First Posted Date: 2011-05-20

Last Posted Date: 2014-12-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT01357213

Locations: 🇺🇸
Johns Hopkins Bayview Medical Center - Infectious Diseases, Baltimore, Maryland, United States

Patients Treated for SCID (1968-Present)

Conditions: XSCID
ADA-SCID
SCID
Omenn Syndrome
Reticular Dysgenesis
Leaky SCID

First Posted Date: 2011-05-02

Last Posted Date: 2020-11-12

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1007

Registration Number: NCT01346150

Locations: 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
University of Texas Southwestern Medical Center Dallas, Dallas, Texas, United States
🇨🇦
The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada

and more 33 locations

TMC207 +/- Rifabutin/Rifampin

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Drug: Rifabutin
Drug: Rifampin
Drug: TMC207

First Posted Date: 2011-04-25

Last Posted Date: 2017-04-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 33

Registration Number: NCT01341184

Locations: 🇺🇸
Case Western Reserve University - Case Medical Center - Infectious Disease & HIV Medicine, Cleveland, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy